ClinicalTrials.gg
CompletedNCT02180997Updated Jun 24, 2016

Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin

A Phase 1 interventional study of Tamsulosin and Solifenacin in LUTS, Benign Prostatic Hyperplasia and Overactive Bladder, sponsored by Jeil Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-24.

Sponsored by Jeil Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Enrollment
38th of 48
36 · median 118
Started
2014
with 5 others
Phase 1
9 of 48
none open now
Registered
17th of 48
by date
Lead sponsor
2 of 48
Jeil Pharmaceutical Co., Ltd.

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 38th largest by enrollment, is one of 6 that started in 2014, is one of 9 in phase 1, and was the 17th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 19 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.

Read the detailed description

Pharmacokinetic Drug Interaction Between Solifenacin 10mg and Tamsulosin 0.4mg in Healthy Male Volunteers

03

Conditions studied

  • LUTS
  • Benign Prostatic Hyperplasia
  • Overactive Bladder

Keywords

  • α1-blockers
  • antimuscarinic agent
04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19\~45 years healthy male
  • Body weight is over 55kg, measurement 18.0kg/m\^2\~ 27.0kg/m\^2
  • Signed form from to participate voluntarily and to comply with the trial requirements.
  • Researchers determined suitable volunteers through physical examination, laboratory tests

Exclusion criteria

Exclusion Criteria:

  • History of liver, kidneys, nervous system, immune system, respiratory, endocrine disorders or tumor or blood disorders, cardiovascular diseases, mental disorders (mood disorders, obsessive-compulsive disorder, etc.)
  • Sitting SBP>150mmHg or \<100mmHg, sitting DBP>100mmHg or \<60mmHg, after 3 minutes break
  • An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
  • Have a gastrointestinal disease history that can affect drug absorption (Crohn's disease ulcers, etc) or surgery (except simple appendectomy or hernia surgery)
  • History of drug abuse
  • Positive urine drug screening
  • Administrated product in a previous clinical trial within 90 days of the first administration day in this study.
  • Donated blood within 60 days prior to the first administration day in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Tamsulosin 1

    Volunteers will be taken Tamsulosin and solifenacin

    Drug: Solifenacin · Drug: Tamsulosin and solifenacin

  • Experimental
    Solifenacin 1

    Volunteers will be taken Tamsulosin and solifenacin

    Drug: Tamsulosin · Drug: Tamsulosin and solifenacin

  • Experimental
    Co-administration 1

    Volunteers will be taken Tamsulosin and solifenacin

    Drug: Tamsulosin · Drug: Solifenacin

  • Experimental
    Tamsulosin 2

    Volunteers will be taken Tamsulosin and solifenacin

    Drug: Solifenacin · Drug: Tamsulosin and solifenacin

  • Experimental
    Solifenacin 2

    Volunteers will be taken Tamsulosin and solifenacin

    Drug: Tamsulosin · Drug: Tamsulosin and solifenacin

  • Experimental
    Co-administration 2

    Volunteers will be taken Tamsulosin and solifenacin

    Drug: Tamsulosin · Drug: Solifenacin

Interventions

  • Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily

    Also known as: Harnal-D tablet

  • Tamsulosin and solifenacin: Solifenacin 10 mg, once daily

    Also known as: Vesicare tablet

  • DrugTamsulosin and solifenacin

    Drug pages: Tamsulosin · Solifenacin

    Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily

    Also known as: Harnal-D and Vesicare tablet

06

What researchers measure

Primary outcomes

  1. AUCτ,ss, Cmax,ss

    Time frame: 192h

Secondary outcomes

  1. C trough,ss

    Time frame: 192h

  2. Tmax,ss

    Time frame: 192h

  3. t1/2

    Time frame: 192h

  4. CL/F

    Time frame: 192h

07

Study locations

1 site
  • Seoul National University Hospital(SNUH)
    Seoul, Jongno-Gu 110-744, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2014
First posted
Jul 3, 2014
Start
Jul 2014
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Last update
Jun 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02180997
Responsible party
Sponsor
First posted
Jul 3, 2014
Start date
Jul 2014
Primary completion
Mar 2015
Completion
Mar 2015
Last update
Jun 24, 2016

Study contacts

Kyung-sang Yu, M.D.,Ph.D.
principal investigator · Seoul National University Hospital(SNUH)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tamsulosin · Solifenacin

Start the discussion